Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Cue Biopharma (Nasdaq: CUE) reported Q4 and full-year 2025 results on March 16, 2026, highlighting a strategic collaboration with ImmunoScape, progress on lead autoimmune candidate CUE-401, and financing actions.
Key metrics: Q4 collaboration revenue of $21.9M, full-year collaboration revenue of $27.5M, cash and equivalents of $27.1M at year-end, net loss for 2025 of $26.6M, and net proceeds of $10.2M from a public offering. The company received $9.5M of a $15M upfront payment and obtained a 40% equity stake in ImmunoScape.
Cue Biopharma (Nasdaq: CUE) will present new in vitro data for lead asset CUE-401 at the World Immune Regulation Meeting (WIRM) in Davos, March 11–14, 2026.
The poster (Session P5) on March 12, 2026 highlights CUE-401’s TGF-β/IL-2 bifunctional design, reporting TGF-β–dependent suppression of proinflammatory cells, prevention of B cell plasma differentiation, NK cell modulation, and expansion of regulatory T cells.
Cue Biopharma (Nasdaq: CUE) reported preclinical safety and tolerability data for lead candidate CUE-401 on Feb 17, 2026. Two non-GLP studies in mice (n=24) and non-human primates (n=6) used step-up IV dosing; all core dose levels were well tolerated with no adverse events observed.
Follow-up NHP repeat dosing showed better tolerability at 1 mg/kg versus 3 mg/kg. Management said an IND filing for CUE-401 is planned in upcoming months.
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as Chief Financial and Business Officer, effective Feb 9, 2026. Ms. Warren has served as Cue’s chief business officer since Sept 2024 and brings 30+ years of global pharma and biotech experience.
Management expects Warren to help advance CUE-401, the company’s lead autoimmune asset, toward clinical development while overseeing financial and business strategy.
Cue Biopharma (Nasdaq: CUE) announced the pricing of an underwritten public offering to raise approximately $10 million in gross proceeds.
The offering consists of 35,714,286 shares of common stock (or pre-funded warrants in lieu) sold together with accompanying common stock warrants to purchase 17,857,143 shares at a combined public offering price of $0.28 per unit (pre-funded warrant units at $0.279). Each warrant has a $0.30 exercise price, is exercisable immediately, and expires five years from issuance.
The offering is expected to close on or about December 22, 2025, subject to customary closing conditions, and underwriters have a 30-day option to purchase up to an additional 5,357,140 shares and/or warrants to purchase 2,678,570 shares.
Cue Biopharma (Nasdaq: CUE) announced on December 18, 2025 that it is commencing an underwritten public offering of its common stock (or pre-funded warrants) together with accompanying warrants to purchase common stock.
The company said it will grant underwriters a 30-day option to purchase up to an additional 15% of the shares and/or warrants. The offering is subject to market and other conditions and will be made by a prospectus supplement to the company’s effective Form S-3 registration statement (File No. 333-271786).
ImmunoScape (CUE) announced an exclusive in-licensing deal with Cue Biopharma (Nasdaq: CUE) on November 13, 2025 to combine Cue's clinical-stage Immuno-STAT® molecules with ImmunoScape’s precision TCR therapy in a novel "Seed-and-Boost" approach for solid tumors.
The program targets the WT1 antigen across multiple solid tumors and hematologic malignancies, has compelling preclinical efficacy, and plans IND-enabling studies to enable clinical trials by 2027. Leadership updates include board appointments of Usman Azam and Adrian Bot, and SAB appointment of Pamela Munster. The platform aims to enable in vivo expansion of tumor-targeting T cells while limiting systemic IL-2 toxicity.
Cue Biopharma (Nasdaq: CUE) reported Q3 2025 results and business highlights on November 12, 2025. Key items: a strategic collaboration and license with ImmunoScape including $15M upfront cash (scheduled $10M in Q4 2025, $5M in Nov 2026) plus a 40% equity stake; leadership transition naming Usman Azam CEO effective Sept 29; clinical update reporting a confirmed 50% ORR and new complete response in the Phase 1 CUE-101 + pembrolizumab trial, with 12‑month OS 88% and median OS 32.7 months.
Quarterly finance highlights: collaboration revenue $2.1M, R&D $4.8M (down from $9.4M), G&A $4.9M (up from $2.9M), net loss $7.45M, and cash and equivalents $11.7M as of Sept 30, 2025.
Cue Biopharma (Nasdaq: CUE) and ImmunoScape announced a collaboration and license to co-develop a novel “Seed-and-Boost” T cell therapy for solid tumors using Cue’s CUE-100 Immuno-STAT molecules paired with ImmunoScape’s proprietary TCRs.
Key terms: Cue is entitled to $15 million upfront ($10M in Q4 2025, $5M in Nov 2026) and a 40% equity stake in ImmunoScape plus eligible high-single-digit royalties. IND-enabling studies are on track for a 2027 IND submission. Preclinical data show activity in pancreatic and ovarian tumor models; CUE-100 Phase 1 datasets reported clinical activity without significant IL-2 toxicities.
Cue Biopharma (Nasdaq: CUE) announced a strategic leadership transition, appointing Dr. Usman "Oz" Azam as President and CEO effective September 29, 2025. Current CEO Daniel Passeri will transition to Strategic Advisor.
Dr. Azam brings over 25 years of drug development leadership experience, including notable roles at Inspirna, Empyrean Neuroscience, Tmunity Therapeutics, and Novartis, where he helped secure the first FDA approval for CAR-T cell therapy. The transition aligns with Cue Biopharma's strategic focus on autoimmune disease, particularly advancing their first-in-class tolerogenic biologic CUE-401, which aims to restore immune homeostasis and potentially revolutionize autoimmune disease treatment.